Association of PD-L1 Expression with Lymph Node Metastasis and Clinical Stage in Ampulla of Vater Cancer: An Observational Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Programmed Death-Ligand 1 (PD-L1) expression is common in ampulla of Vater cancer. PD-L1 positivity correlates with advanced clinical stage and lymph node metastasis, suggesting its potential as a prognostic marker.
Area Of Science
- Oncology
- Immunology
- Gastroenterology
Background
- Ampulla of Vater cancer is a periampullary malignancy originating from pancreatic and bile ducts.
- Programmed Death-Ligand 1 (PD-L1) plays a key role in cancer progression, immune evasion, and the tumor microenvironment.
Purpose Of The Study
- To investigate the association between PD-L1 expression and clinical characteristics in ampulla of Vater cancer patients.
Main Methods
- Retrospective observational study including 44 patients with ampulla of Vater cancer.
- PD-L1 expression assessed via immunohistochemistry.
- Clinicopathological data analyzed using chi-square, Mann-Whitney, and independent t-tests.
Main Results
- PD-L1 expression was positive in 59.1% of patients.
- PD-L1 positivity was significantly associated with lymph node involvement (p=0.042) and advanced clinical stage (p=0.017).
- No significant association found with age, sex, histopathological grade, or distant metastasis.
Conclusions
- PD-L1 expression in ampulla of Vater cancer is linked to increased lymph node metastasis and advanced clinical stage.
- PD-L1 may serve as a prognostic biomarker and a potential therapeutic target for this cancer subtype.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.